1. Home
  2. CRTO vs TBPH Comparison

CRTO vs TBPH Comparison

Compare CRTO & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Criteo S.A.

CRTO

Criteo S.A.

HOLD

Current Price

$16.41

Market Cap

780.6M

ML Signal

HOLD

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$16.99

Market Cap

824.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRTO
TBPH
Founded
2005
2013
Country
France
United States
Employees
3649
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
780.6M
824.9M
IPO Year
2013
2013

Fundamental Metrics

Financial Performance
Metric
CRTO
TBPH
Price
$16.41
$16.99
Analyst Decision
Strong Buy
Buy
Analyst Count
10
6
Target Price
$34.00
$18.40
AVG Volume (30 Days)
235.3K
304.2K
Earning Date
05-06-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
38.95
279.13
EPS
0.15
2.06
Revenue
$2,296,692,000.00
$15,386,000.00
Revenue This Year
N/A
$8.46
Revenue Next Year
$5.54
N/A
P/E Ratio
$5.92
$8.25
Revenue Growth
27.65
N/A
52 Week Low
$15.58
$8.33
52 Week High
$28.91
$21.03

Technical Indicators

Market Signals
Indicator
CRTO
TBPH
Relative Strength Index (RSI) 37.25 59.89
Support Level N/A $16.14
Resistance Level $20.10 $17.24
Average True Range (ATR) 0.90 0.40
MACD -0.31 0.01
Stochastic Oscillator 18.63 86.47

Price Performance

Historical Comparison
CRTO
TBPH

About CRTO Criteo S.A.

Criteo SA is an ad-tech company in the digital advertising market. Its technology allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. Retail Media: This segment encompasses revenue generated from brands, agencies, and retailers for the purchase and sale of retail media digital advertising inventory and audiences, and services. Performance Media: This segment encompasses targeting capabilities and supply and AdTech services. The majority of its revenues is generated from the performance media segment.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.

Share on Social Networks: